logo-loader
viewOncimmune

Oncimmune awarded the 'Winning in Business in Spain' award at the Department for International Trade's UK-Spain Business Awards

The awards celebrate the extensive commercial relationships between the United Kingdom and Spain

Spanish flag

Oncimmune Holdings PLC (LON:ONC), a leading global immunodiagnostics group, has been awarded the 'Winning in Business in Spain' award at the Department for International Trade's (DIT) UK-Spain Business Awards held on 20 February 2020 at the Madrid Stock Exchange.

The awards celebrate the extensive commercial relationships between the United Kingdom and Spain.

READ: Oncimmune eyes US launch for lung cancer diagnostic; has strong deal pipeline

The DIT's introduction of Sabartech has enabled Oncimmune to build its successful distribution partnership with Sabartech, which has led to making EarlyCDT Lung available in Spain and Portugal.

Dr Adam M Hill, CEO of Oncimmune commented: “This award is testament to the strong relationship we have fostered with Sabartech. Every year there are 23,000 lung cancer deaths in Spain1.

“The key to improving lung cancer survival is early detection and we are delighted that our EarlyCDT Lung test is continuing to gain momentum in screening in Spain and beating cancer, one test at a time."

Javier Sarasqueta, co-founder and CEO of Sabartech said "Sabartech and Oncimmune have developed a great partnership that has helped launch EarlyCDT Lung in the Spanish market. We are looking forward to building on this to improve the early detection of lung cancer in both the private and public healthcare systems. This award is a fantastic recognition of all we have achieved so far."

Quick facts: Oncimmune

Price: 96.5 GBX

AIM:ONC
Market: AIM
Market Cap: £61.28 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Oncimmune named herein, including the promotion by the Company of Oncimmune in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: FTSE 100 unsettled by Whitbread rights issue and spike in...

Headlines from the Proactive UK newsroom. The FTSE 100 slipped early unsettled by Whitbread’s rights issue and a spike in coronavirus cases overseas. The index was down 35 at 6,031 early doors. Whitbread is to raise £1bn through a rights issue at 1,500p, a thumping 47% discount to last...

4 days, 14 hours ago

2 min read